Elan goes on the block in the final hour of takeover fight

Elan is officially up for sale. Seeking to dodge a hostile takeover bid from Royalty Pharma, the Irish company said Friday morning that it has begun a formal sales process, Reuters reports, and invited Royalty to participate. In voting Friday, sharedholders voted down three of four proposals standing in the way of a buyout by Royalty. A source told Reuters that Elan has attracted the interest of several mid-sized drug companies. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.